The payer backlash against PTC’s deflazacort for Duchenne MD begins with some damning comparison shopping
PTC Therapeutics has a few weeks to go before it wraps its $190 million deal to buy the controversial drug deflazacort from Marathon Pharmaceuticals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
